Related references
Note: Only part of the references are listed.Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
Douglas G. Day et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2013)
Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients
Gemma Caterina Maria Rossi et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2013)
Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication
Sudipta Ghosh et al.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2012)
Economic impact of primary open-angle glaucoma in Australia
Mohamed Dirani et al.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2011)
Prevalence of Ocular Surface Complaints in Patients With Glaucoma Using Topical Intraocular Pressure-Lowering Medications
Robert D. Fechtner et al.
CORNEA (2010)
Ocular Surface Tolerability of Prostaglandin Analogs in Patients with Glaucoma or Ocular Hypertension
Jess T. Whitson et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2010)
Prevalence of Dry Eye Disease Among US Men Estimates From the Physicians' Health Studies
Debra A. Schaumberg et al.
ARCHIVES OF OPHTHALMOLOGY (2009)
Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma
Christophe Baudouin
ACTA OPHTHALMOLOGICA (2008)
Prevalence of ocular surface disease in glaucoma patients
Eamon W. Leung et al.
JOURNAL OF GLAUCOMA (2008)
The epidemiology of age related eye diseases in Asia
TY Wong et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2006)
Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study
EM Chia et al.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2003)
Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension
LJ Katz
JOURNAL OF GLAUCOMA (2002)
Share Paper
